Compare uniQure N.V. Ordinary Shares (QURE) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs Vir Biotechnology Inc. Common Stock — how do they compare? uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Vir Biotechnology Inc. Common Stock is the larger of the two by market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| QURE | VIR | |
|---|---|---|
Market Cap | $1.48B | $1.80B |
Volume | 2,488,780 | 1,782,836 |
Sector | Health | Health |
52-Week High | $70.59 | $11.78 |
52-Week Low | $9.03 | $5.12 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $728.62M | $1.36B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About Vir Biotechnology Inc. Common Stock
Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →
